Artificial intelligence ramped up in 2016, but has to prove its utility in 2017
27 December 2016
According to MedyMatch Chief Financial Officer Michael Rosenberg, 2016 was a banner year for artificial intelligence. How does he know? “Even my mother knows what it is now. It’s going mainstream.”
The top trends for med tech in 2017
27 December 2016
If 2016 was the year that med tech players bet big on emerging and exciting technologies, 2017 will be the year to buckle down, generate evidence of the new tech’s utility and find its niche in the industry. This year, numerous companies made moves in artificial intelligence, while GlaxoSmithKline and Verily threw down $715 million on a bioelectronics-oriented joint venture. Meanwhile, M&A and venture capital funding took a dip, and a few events highlighted current and future cybersecurity risks that may materialize as med tech becomes more connected.
Biotech IPO market slowdown—will it continue into 2017?
26 December 2016
This year will not go down as a classic for biotech IPOs; in fact, it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that almost all of the biotech IPOs that priced since the first quarter have broken issue, and were trading below their offer price.
As the dust settles on Cures, what will it mean for biopharma R&D?
23 December 2016
At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017 and beyond.
The top biopharma trends of 2016, and looking ahead to 2017
23 December 2016
It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will bring.
Biosimilars Supporting Contract Manufacturers’ Growth
21 December 2016
Biosimilars are finally becoming mainstream global products, including more than 20 having received approval in the European Union. The United States has been a prominent country lagging behind in its biosimilars approvals, with four approved by FDA. But many more approvals are on the way. This article examines impacts biosimilars are having on the biopharmaceutical contract manufacturing organization (CMO) sector. This includes capacity needs, and where biosimilars are requiring improved services, particularly related to biosimilarity testing and bioassays.
PWC “Top health industry issues of 2017: A year of uncertainty and opportunity”.
21 December 2016
PwC Health Research Institute’s annual report highlights the forces that are expected to have the most impact on the healthcare industry in the coming year.
Patient connections will be key in pharma's year of 'opportunity,' PwC says
21 December 2016
PwC's pharma and healthcare predictions for 2017 are out. And though, yes, next year may be "a year of uncertainty" with U.S. President-elect Donald Trump set to step in, it's also a year of "opportunity," the consultancy says.
Big Pharma’s business model is broken; New drug OKs plunged this year, highlighting an ugly reality
19 December 2016
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry. Big Pharma’s business model is broken, so change it. When your accountant tells you the business you’re running is unsustainable, it’s a good idea to pay very, very close attention to the details. So it is with Big Pharma and drug development, a game which the largest players in the industry have not mastered.
Gene mutation causes two heart conditions, spotlights new drug target
19 December 2016
Scientists studying one family’s genetics to better understand congenital heart disease have discovered more than they bargained for. They found that a mutation that causes babies to be born with a hole in the heart also causes heart failure in adolescence. The findings have uncovered a potential new target for heart disease.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024